Lesson plan

Α5IA

α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor. It binds to α 1 , α 2 , α 3 and α 5 -containing subtypes, with functional selectivity for α 5 -containing subtypes.

Back to article

Article summary

α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor. It binds to α 1 , α 2 , α 3 and α 5 -containing subtypes, with functional selectivity for α 5 -containing subtypes.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.